Julie Oja, PA
Medical · Moosic, PANPI 1548365166
Payments from drug & device makers
Across 590 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$940
- Alkermes, Inc.$864
- Otsuka America Pharmaceutical, Inc.$769
- Bausch Health US, LLC$615
- plus $4K from 24 others
What the payments were for
- Food & beverage$8,87097%
- Education$3143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 74 | $1,108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $1,082 |
| AbbVie | 64 | $940 |
| Alkermes, Inc. | 48 | $864 |
| Otsuka America Pharmaceutical, Inc. | 45 | $769 |
| Bausch Health US, LLC | 33 | $615 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $518 |
| Johnson & Johnson | 34 | $468 |
| Neurocrine Biosciences, Inc. | 35 | $457 |
| Lundbeck LLC | 32 | $409 |
| Vanda Pharmaceuticals Inc. | 19 | $327 |
| Eisai Inc. | 12 | $239 |
| Axsome Therapeutics, Inc. | 9 | $159 |
| Novo Nordisk | 10 | $149 |
| Corium, LLC | 13 | $113 |
| Merck | 7 | $110 |
| Almatica Pharma LLC | 6 | $106 |
| Sage Therapeutics, LLC | 4 | $94 |
| E.r. Squibb & Sons, L.L.C. | 6 | $87 |
| Indivior Inc. | 5 | $80 |
| Noven Therapeutics, LLC | 4 | $80 |
| Biogen | 4 | $71 |
| Alfasigma USA, Inc. | 3 | $60 |
| Acadia Pharmaceuticals Inc | 3 | $53 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Supernus Pharmaceuticals, Inc. | 3 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Neos Therapeutics, LP | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
How this compares
$9,184 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 42 | $380,343 |
| RexultiBrexpiprazole | 19 | $28,537 |
| VraylarCariprazine Hcl | 18 | $25,244 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $21,667 |
| FetzimaLevomilnacipran Hcl | 26 | $21,299 |
| AplenzinBupropion Hbr | 11 | $21,230 |
| TrintellixVortioxetine Hydrobromide | 36 | $18,489 |
| SaphrisAsenapine Maleate | 13 | $15,357 |
| Lurasidone Hcl | 42 | $11,885 |
| Fluphenazine Hcl | 30 | $10,112 |
| BelsomraSuvorexant | 21 | $8,205 |
| Vilazodone Hcl | 79 | $6,514 |
| Lisdexamfetamine Dimesylate | 20 | $5,843 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 83 | $4,867 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,108 | $380,34342 claims |
| AbbVieVraylar, Fetzima, Saphris | $940 | $61,90157 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $769 | $28,53719 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $518 | $23,01248 claims |
| Alkermes, Inc.Lybalvi | $864 | $21,66714 claims |
| Bausch Health US, LLCAplenzin | $615 | $21,23011 claims |
| MerckBelsomra | $110 | $8,20521 claims |
| Almatica Pharma LLCSertraline Hcl | $106 | $1,538144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Moosic
- Casey KasiskyMoosic$24K
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.